Cellenkos presents promising phase 1b data for CK0804 in myelofibrosis

New cell therapy shows potential in treating advanced blood disorder

Cellenkos has unveiled new phase 1b data for its T-regulatory cell therapy candidate, CK0804, at the 66th Annual Meeting & Exposition of the American Society of Hematology (ASH).

The results highlighted safety and efficacy in patients with myelofibrosis who did not respond to standard treatments.

“There is a significant need for new therapeutic options for patients living with myelofibrosis who have suboptimal responses to approved JAK inhibitors,” said Simrit Parmar, MD, Founder of Cellenkos. She emphasised the potential of CK0804, a CXCR4-enriched Treg cell therapy, to home to the bone marrow and address inflammatory pathways in this debilitating disease.

The study demonstrated reductions in spleen volume and symptom burden, with patients showing improvement in fatigue and early satiety. “We are greatly encouraged by the safety profile and early signs of efficacy observed in this patient cohort,” added Dr Parmar.

The trial involved six CXCR4-enriched Treg infusions administered every four weeks, showing no need for lymphodepletion or HLA matching.

Encouraging results included significant reductions in pro-inflammatory cytokines and improvements in transfusion requirements for some patients.

Cellenkos is now advancing the study with an expansion cohort to evaluate a modified dosing regimen for patients with high inflammation levels.

Cellenkos’ Treg therapies aim to treat a range of inflammatory and autoimmune conditions, with CK0804 showing promise in myelofibrosis.

The company’s CK0801 candidate for aplastic anaemia has also demonstrated efficacy, including transfusion independence.

“Our latest clinical data show that GDF-15 neutralisation with visugromab not only enhances immune response but also alleviates the symptoms of cachexia, offering a dual benefit for patients,” said Dr Eugen Leo, Chief Medical Officer at CatalYm.

These findings support the continued development of CK0804 for myelofibrosis patients.